Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2418753 | 0.88 | HTT (0.51) | CYP3A4CYP3A5HTTGRM2KMT2A | |
| SCHEMBL4946642 | 0.83 | CHRNB2 (0.51) | CYP3A4CYP3A5HTTPOLBHPGD | |
| SCHEMBL29854164 | 0.83 | CHRNB2 (0.51) | CYP3A4CYP3A5HTTPOLBHPGD | |
| Trifluoroacetic Acid SCHEMBL3635392 | 0.78 | NPC1 (0.57) | CYP3A4CYP3A5HTTPOLBHPGD | |
| SCHEMBL238960 | 0.78 | HTT (0.58) | HTTKMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL2418756 | 0.77 | HTT (0.46) | CYP3A4CYP3A5HTTGRM2KMT2A | |
| Trifluoroacetic Acid SCHEMBL2413465 | 0.76 | ALOX15 (0.51) | SMN1; SMN2ALDH1A1LMNACHRNB2CHRNA4 | |
| SCHEMBL28026367 | 0.76 | CHRNB2 (0.46) | CYP3A4CYP3A5HTTGRM2LMNA | |
| SCHEMBL28026369 | 0.76 | CHRNB2 (0.46) | CYP3A4CYP3A5HTTGRM2LMNA | |
| SCHEMBL14477064 | 0.73 | CHRNB2 (0.49) | CYP3A4CYP3A5HTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | CYP3A4 4521/4885CYP3A5 4862/4885HTT 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.